SMAD3 and neoplasm: Finally, we analysed the activation of SMAD3 in the GARP++ and NT tumours by IHC and observed an increased fraction of cells with high SMAD3-phosphorylation in GARP++ tumours compared to NT tumours (Fig. 3F).